Details for Patent: 8,791,270
✉ Email this page to a colleague
Which drugs does patent 8,791,270 protect, and when does it expire?
Patent 8,791,270 protects BELRAPZO, BENDEKA, and TREANDA, and is included in three NDAs.
Protection for TREANDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-four patent family members in twenty countries.
Summary for Patent: 8,791,270
| Title: | Bendamustine pharmaceutical compositions |
| Abstract: | The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases. |
| Inventor(s): | Brittain; Jason Edward (El Cajon, CA), Franklin; Joe Craig (Tulsa, OK) |
| Assignee: | Cephalon, Inc. (Frazer, PA) |
| Application Number: | 13/969,724 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,791,270 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Use; |
Drugs Protected by US Patent 8,791,270
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharms | BELRAPZO | bendamustine hydrochloride | SOLUTION;INTRAVENOUS | 205580-001 | May 15, 2018 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | ⤷ Sign Up | ||
| Eagle Pharms | BELRAPZO | bendamustine hydrochloride | SOLUTION;INTRAVENOUS | 205580-001 | May 15, 2018 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA | ⤷ Sign Up | ||
| Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA | ⤷ Sign Up | |||
| Cephalon | TREANDA | bendamustine hydrochloride | POWDER;IV (INFUSION) | 022249-002 | May 1, 2009 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,791,270
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 052877 | ⤷ Sign Up | |||
| Australia | 2006204817 | ⤷ Sign Up | |||
| Brazil | PI0606332 | ⤷ Sign Up | |||
| Canada | 2593582 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
